Piercey Cianna J, Hetelekides Eleftherios, Karoly Hollis C
Department of Psychology, Colorado State University, Fort Collins, CO, 80521, USA.
J Cannabis Res. 2024 Jul 11;6(1):29. doi: 10.1186/s42238-024-00235-x.
Most studies examining the simultaneous use of cannabis with other drugs have focused on cannabis and alcohol, with fewer studies examining simultaneous use of cannabis with other drugs. The United States is currently experiencing an upward trend in psychedelic use and there is an increasing need to characterize cannabis and psychedelic drug interactions to best inform public health recommendations.
A mixed methods field study design was used to survey participants (N = 128) on their lifetime co-use of cannabis with other drugs. Participants who reported lifetime co-use of cannabis and psychedelics (N = 63) were then asked open-ended questions about their most recent simultaneous co-use experience (i.e., how cannabis enhanced their psychedelic experience and whether they experienced any adverse reactions). We conducted a thematic analysis of responses describing how cannabis enhanced the psychedelic experience (N = 54). However, due to low response rate for participants reporting an adverse reaction (N = 7, 11.1%), responses to this question were not analyzed thematically and are instead presented individually.
Themes included tension reduction and balancing of drug effects (N = 27, 50%), enhancement to psychological processes (N = 11, 20.4%), intensified psychedelic drug effects (N = 12, 22.2%), enhanced psychedelic come-down experience (N = 8, 14.8%), and overall ambiguous enhancement (N = 7, 13%). Among participants reporting an adverse reaction, individual responses included increased anxiety and intensity of the experience, decreased sociability, increased negative affect, sleepiness, disassociation, and confusion.
Additional research is warranted to better characterize cannabis and psychedelic drug interactions to best inform public health recommendations.
大多数研究同时使用大麻与其他药物的情况时,都集中在大麻与酒精上,而研究大麻与其他药物同时使用的情况较少。美国目前迷幻药的使用呈上升趋势,因此越来越需要了解大麻与迷幻药的相互作用,以便为公共卫生建议提供最佳依据。
采用混合方法实地研究设计,对参与者(N = 128)进行关于其一生中大麻与其他药物共同使用情况的调查。然后,对报告一生中同时使用过大麻和迷幻药的参与者(N = 63),就其最近一次同时使用的经历提出开放式问题(即大麻如何增强其迷幻体验以及他们是否经历过任何不良反应)。我们对描述大麻如何增强迷幻体验的回答进行了主题分析(N = 54)。然而,由于报告有不良反应的参与者回复率较低(N = 7,11.1%),因此对该问题的回答未进行主题分析,而是单独列出。
主题包括减轻紧张和平衡药物效果(N = 27,50%)、增强心理过程(N = 11,20.4%)、强化迷幻药效果(N = 12,22.2%)、增强迷幻药消退体验(N = 8,14.8%)以及总体上的模糊增强(N = 7,13%)。在报告有不良反应的参与者中,个人回复包括焦虑增加、体验强度增加、社交能力下降、负面影响增加、嗜睡、解离和困惑。
有必要进行更多研究,以更好地描述大麻与迷幻药的相互作用,从而为公共卫生建议提供最佳依据。